Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 4,379 Cr.
- Current Price ₹ 951
- High / Low ₹ 1,007 / 491
- Stock P/E 318
- Book Value ₹ 155
- Dividend Yield 0.00 %
- ROCE 2.15 %
- ROE 0.84 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 6.20 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.99% over last 3 years.
- Earnings include an other income of Rs.38.8 Cr.
- Company has high debtors of 243 days.
- Working capital days have increased from -372 days to 105 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 8 | 14 | 12 | 34 | 39 | 96 | |
| 7 | 12 | 14 | 34 | 46 | 99 | |
| Operating Profit | 1 | 1 | -2 | -0 | -7 | -3 |
| OPM % | 13% | 9% | -14% | -0% | -19% | -3% |
| 0 | 1 | 7 | 7 | 22 | 39 | |
| Interest | 0 | 1 | 2 | 3 | 7 | 7 |
| Depreciation | 1 | 1 | 1 | 2 | 3 | 10 |
| Profit before tax | 0 | 1 | 2 | 2 | 5 | 18 |
| Tax % | -110% | 18% | 38% | 60% | 28% | |
| 1 | 1 | 1 | 1 | 4 | 14 | |
| EPS in Rs | 2.21 | 0.69 | 1.22 | 0.27 | 0.80 | 3.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 42% |
| TTM: | 157% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 76% |
| TTM: | 936% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 80% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 4 | 9 | 10 | 31 | 46 | 46 |
| Reserves | 6 | 25 | 29 | 138 | 662 | 668 |
| 4 | 15 | 61 | 101 | 103 | 67 | |
| 2 | 7 | 12 | 17 | 23 | 36 | |
| Total Liabilities | 15 | 55 | 112 | 286 | 834 | 817 |
| 2 | 2 | 8 | 24 | 55 | 85 | |
| CWIP | 3 | 3 | 11 | 18 | 34 | 12 |
| Investments | 1 | 12 | 8 | 82 | 104 | 141 |
| 9 | 39 | 84 | 162 | 641 | 578 | |
| Total Assets | 15 | 55 | 112 | 286 | 834 | 817 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -3 | -24 | -43 | -19 | -20 | |
| -4 | -10 | -5 | -57 | -163 | |
| 8 | 34 | 47 | 87 | 533 | |
| Net Cash Flow | 1 | -0 | -2 | 10 | 349 |
| Free Cash Flow | -6 | -25 | -52 | -39 | -70 |
| CFO/OP | -280% | -2,062% | 2,412% | 30,117% | 260% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 11 | 226 | 464 | 236 | 243 |
| Inventory Days | 31 | 133 | 194 | 121 | 299 |
| Days Payable | 12 | 269 | 273 | 310 | 452 |
| Cash Conversion Cycle | 30 | 89 | 385 | 47 | 90 |
| Working Capital Days | 197 | 102 | -566 | -656 | 105 |
| ROCE % | 5% | 6% | 3% | 2% |
Insights
In beta| Mar 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Annual Installed Capacity (API Manufacturing) MTPA |
|
||
| Approved ANDA Products/Strengths (Regulated Markets) Number |
|||
| Approved ANDAs (Regulated Markets) Number |
|||
| Approved Products (Emerging Markets) Number |
|||
| CDMO/CMO Commercialized Products Number |
|||
| Commercialized ANDAs (Regulated Markets) Number |
|||
| Pipeline Products/Applications Filed (Emerging Markets) Number |
|||
| Revenue Realization per Unit (Emerging Markets) INR |
|||
| Annual Installed Capacity (Atlanta OSD Facility) Million Units |
|||
| Annual Installed Capacity (Chhatral General Oral Dosage) Million Units |
|||
Extracted by Screener AI
Documents
Announcements
- Financial Results For Quarter And Financial Year Ended March 31, 2026 2m
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 14, 2026
9m - Board approved FY26 audited results; CS Vinay Kumar Mishra resigns effective June 10, 2026; Sharp & Tannan appointed internal auditor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST.
-
Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters
8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.
Concalls
-
Jan 2026Transcript PPT REC
-
Dec 2025TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.